Inventor · disambiguated record
Andrew D. Levin
Also filed as: LEVIN ANDREW D
18 granted patents·17 pending applications·92 citations·filing 1998–2025
93Inventor score
Files withIMBRIA PHARMACEUTICALS INC18AEROVATE THERAPEUTICS INC4ELIEM THERAPEUTICS INC4ARCUATE THERAPEUTICS INC2ATHENEN THERAPEUTICS INC2
Top patents by PatentIndex Score
35 records- 0196US11376330B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2020·Granted Jul 5, 2022·13 cites·6 claims
- 0296US10556013B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2018·Granted Feb 11, 2020·27 cites·5 claims
- 0395US11844840B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2022·Granted Dec 19, 2023·3 cites·5 claims
- 0495US10953102B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Mar 23, 2021·15 cites·6 claims
- 0594US11229650B2Inhalable imatinib formulations, manufacture, and uses thereofAEROVATE THERAPEUTICS INC·Filed 2020·Granted Jan 25, 2022·4 cites·14 claims
- 0694US10918728B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Feb 16, 2021·14 cites·4 claims
- 0792US11298355B2Inhalable imatinib formulations, manufacture, and uses thereofAEROVATE THERAPEUTICS INC·Filed 2020·Granted Apr 12, 2022·3 cites·15 claims
- 0891US11806349B2Inhalable imatinib formulations, manufacture, and uses thereofAEROVATE THERAPEUTICS INC·Filed 2022·Granted Nov 7, 2023·1 cites·20 claims
- 0991US11090314B2Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereofATHENEN THERAPEUTICS INC·Filed 2020·Granted Aug 17, 2021·3 cites·14 claims
- 1090US11571432B2Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereofELIEM THERAPEUTICS INC·Filed 2021·Granted Feb 7, 2023·2 cites·10 claims
- 1188US10857163B1Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereofATHENEN THERAPEUTICS INC·Filed 2019·Granted Dec 8, 2020·3 cites·8 claims
- 1286US12318453B2Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2023·Granted Jun 3, 2025·0 cites·5 claims
- 1386US2024108622A1Inhalable imatinib formulations, manufacture, and uses thereofAEROVATE THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1484US2025262310A1Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1582US12318382B2Methods of treating rheumatic diseases using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2019·Granted Jun 3, 2025·3 cites·11 claims
- 1681US10933037B2N-acylethanolamide derivatives and uses thereofELIEM THERAPEUTICS INC·Filed 2017·Granted Mar 2, 2021·1 cites·11 claims
- 1776US2023147799A1Compositions that preferentially potentiate subtypes of gabaa receptors and methods of use thereofELIEM THERAPEUTICS UK LTD·Filed 2022·Application pending·0 cites
- 1867US11547681B2N-acylethanolamide derivatives and uses thereofELIEM THERAPEUTICS INC·Filed 2020·Granted Jan 10, 2023·0 cites·15 claims
- 1967US2019216936A1Compositions and methods for increasing efficiency of cardiac metabolismIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2065US2020352894A1Combination therapyIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2163US10786476B2Combination therapyIMBRIA PHARMACEUTICALS INC·Filed 2017·Granted Sep 29, 2020·0 cites·2 claims
- 2258US2020407395A1Chiral peptidesARCUATE THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2357US10870678B2Chiral peptidesARCUATE THERAPEUTICS INC·Filed 2017·Granted Dec 22, 2020·0 cites·14 claims
- 2452US2023372365A1Methods of treating fibromyalgia with neuroactive steroidsLEVIN ANDREW D·Filed 2021·Application pending·0 cites
- 2552US2023210870A1Methods of treating female health conditions related to sex hormonesELIEM THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2651US2022226313A1Combination therapies that include an agent that promotes glucose oxidation and an inhibitor of pyruvate dehydrogenase kinaseIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 2750US2022202803A1Combination therapies including inhibitors of dihydroorotate dehydrogenaseCLEAR CREEK BIO INC·Filed 2020·Application pending·0 cites
- 2849US2021401833A1Modified release formulations of modified forms of trimetazidineIMBRIA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 2946US2021346329A1Tca cycle intermediates and methods of use thereofIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3045US2020369594A1Compounds comprising short-chain fatty acid moieties and compositions and methods thereofCARNOT3 LLC·Filed 2019·Application pending·0 cites
- 3144US2020140375A1Compositions and methods for treating conditions associated with altered tca cycle metabolismIMBRIA PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 3244US2022249463A1Methods of altering cardiac remodeling using compounds that promote glucose oxidationIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3343US2022168431A1Methods of treating cancer using trimetazidine-based compoundsIMBRIA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3438US2021346332A1Compositions and methods for treating and preventing leber's hereditary optic neuropathyIMBRIA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 3526US5979280AElectronics board assembly apparatus comprising an indexed punchINTEL CORP·Filed 1998·Granted Nov 9, 1999·0 cites·13 claims
Join the waitlist — get patent alerts
Get an alert when Andrew D. Levin files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →